Samantha (Sam) Lewis Acquires 153 Shares of CSL (ASX:CSL) Stock

CSL Limited (ASX:CSL) insider Samantha (Sam) Lewis purchased 153 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was acquired at an average price of A$151.56 per share, for a total transaction of A$23,188.07.

CSL Price Performance

The firm has a market cap of $77.43 billion, a PE ratio of 28.02, a price-to-earnings-growth ratio of 1.29 and a beta of 0.32. The company has a debt-to-equity ratio of 64.46, a current ratio of 1.86 and a quick ratio of 1.68.

CSL Announces Dividend

The business also recently announced a Interim dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Wednesday, April 8th will be given a dividend of $1.837 per share. The ex-dividend date of this dividend is Monday, March 9th. This represents a dividend yield of 121.0%. CSL’s payout ratio is 50.38%.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.